At the very moment a better coronavirus vaccine is expected to finally become available, America’s vaccination program is feeling the effects of a long period of retreat.
Local programs to bring shots to the places where Americans gather and the institutions they trust have folded, a consequence in some cases of congressional resistance to more pandemic response spending.
The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said. ...
The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection. That’s consistent with earlier results used to authorize the drug in the U.S. and other nations.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/7IGDLXTOKNP2NNJELQWVYZRMPA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZBBNOWWNSFLNHGJ3NOUT4JRP5I.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YSPCY76QJFLNDBFB7KHOZNHMTA.jpg)
